Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Comparison of BMD Measurement by DEXA to BeamMed Speed-of-Sound Measurement at Forearm in Patients With Gaucher Disease

This study has been completed.
Information provided by (Responsible Party):
Ari Zimran, Shaare Zedek Medical Center Identifier:
First received: January 27, 2014
Last updated: November 18, 2014
Last verified: November 2014
The purpose of this study is to compare the accuracy and comparability and secondarily to assess the values achieved by measurement of the forearm BMD by DXA and SOS by BeamMed, relative to standard DXA evaluations at the FN and LS.

Condition Intervention
Gaucher Disease Type 1
Device: BeamMed Speed-of-Sound bone strength test at forearm

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
Official Title: Comparison of BMD Measurements by Dual Energy X-Ray Absorptiometry and Multiple Sites to BeamMed Speed-of-Sound Measurements at the Forearm in Patients With Gaucher Disease

Resource links provided by NLM:

Further study details as provided by Shaare Zedek Medical Center:

Primary Outcome Measures:
  • BMD measurements by DEXA and SOS [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • T-score and Z-score by DEXA and SOS [ Time Frame: 6 months ]

Enrollment: 100
Study Start Date: February 2014
Study Completion Date: September 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SOS forearm test
BeamMed Speed-of-Sound bone strength test at forearm
Device: BeamMed Speed-of-Sound bone strength test at forearm
BeamMed Speed-of-Sound bone strength test at forearm in addition to the DEXA test

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age: >18
  • Gaucher disease type 1
  • Able to undergo a DEXA test

Exclusion Criteria:

  • Minors
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02067247

Shaare Zedek Medical Center
Jerusalem, Israel
Sponsors and Collaborators
Shaare Zedek Medical Center
Principal Investigator: Ari Zimran, Prof. Shaare Zedek Medical Center
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Ari Zimran, Prof., Shaare Zedek Medical Center Identifier: NCT02067247     History of Changes
Other Study ID Numbers: DEXA-SOS
Study First Received: January 27, 2014
Last Updated: November 18, 2014

Additional relevant MeSH terms:
Gaucher Disease
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders
Central Nervous System Stimulants
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors processed this record on April 26, 2017